Eradication of JAK2 V617F mutation after allogeneic transplantation in a patient with myelofibrosis with myeloid metaplasia

被引：5

作者：

Fiorini, A. ^{[1
]}

Reddiconto, G. ^{[1
]}

Farina, G. ^{[1
]}

Marietti, S. ^{[1
]}

Palladino, M. ^{[1
]}

Chiusolo, P. ^{[1
]}

Leone, G. ^{[1
]}

Sica, S. ^{[1
]}

机构：

[1] Catholic Univ Rome, Inst Hematol, Rome, Italy

来源：

LEUKEMIA | 2006年 / 20卷 / 12期

关键词：

D O I：

10.1038/sj.leu.2404430

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：2198 / 2199

页数：2

共 11 条

[1] The Italian consensus conference on diagnostic criteria for myelofibrosis with myeloid metaplasia [J].

Barosi, G ;

Ambrosetti, A ;

Finelli, C ;

Grossi, A ;

Leoni, P ;

Liberato, NL ;

Petti, MC ;

Pogliani, E ;

Ricetti, M ;

Rupoli, S ;

Visani, G ;

Tura, S .

BRITISH JOURNAL OF HAEMATOLOGY, 1999, 104 (04) :730-737

[2] A PROGNOSTIC CLASSIFICATION OF MYELOFIBROSIS WITH MYELOID METAPLASIA [J].

BAROSI, G ;

BERZUINI, C ;

LIBERATO, LN ;

COSTA, A ;

POLINO, G ;

ASCARI, E .

BRITISH JOURNAL OF HAEMATOLOGY, 1988, 70 (04) :397-401

[3] Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders [J].

Baxter, EJ ;

Scott, LM ;

Campbell, PJ ;

East, C ;

Fourouclas, N ;

Swanton, S ;

Vassiliou, GS ;

Bench, AJ ;

Boyd, EM ;

Curtin, N ;

Scott, MA ;

Erber, WN ;

Green, AR .

LANCET, 2005, 365 (9464) :1054-1061

[4] Myelofibrosis with myeloid metaplasia: Diagnosis, prognostic factors, and staging [J].

Cervantes, F ;

Barosi, G .

SEMINARS IN ONCOLOGY, 2005, 32 (04) :395-402

[5] Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia [J].

Devine, SM ;

Hoffman, R ;

Verma, A ;

Shah, R ;

Bradlow, BA ;

Stock, W ;

Maynard, V ;

Jessop, E ;

Peace, D ;

Huml, M ;

Thomason, D ;

Chen, YH ;

van Besien, K .

BLOOD, 2002, 99 (06) :2255-2258

[6]

Dupriez B, 1996, BLOOD, V88, P1013

[7] A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera [J].

James, C ;

Ugo, V ;

Le Couédic, JP ;

Staerk, J ;

Delhommeau, F ;

Lacout, C ;

Garçon, L ;

Raslova, H ;

Berger, R ;

Bennaceur-Griscelli, A ;

Villeval, JL ;

Constantinescu, SN ;

Casadevall, N ;

Vainchenker, W .

NATURE, 2005, 434 (7037) :1144-1148

[8] A gain-of-function mutation of JAK2 in myeloproliferative disorders [J].

Kralovics, R ;

Passamonti, F ;

Buser, AS ;

Teo, S ;

Tiedt, R ;

Passweg, JR ;

Tichelli, A ;

Cazzola, M ;

Skoda, RC .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (17) :1779-1790

[9] Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis [J].

Levine, RL ;

Wadleigh, M ;

Cools, J ;

Ebert, BL ;

Wernig, G ;

Huntly, BJP ;

Boggon, TJ ;

Wlodarska, L ;

Clark, JJ ;

Moore, S ;

Adelsperger, J ;

Koo, S ;

Lee, JC ;

Gabriel, S ;

Mercher, T ;

D'Andrea, A ;

Fröhling, S ;

Döhner, K ;

Marynen, P ;

Vandenberghe, P ;

Mesa, RA ;

Tefferi, A ;

Griffin, JD ;

Eck, MJ ;

Sellers, WR ;

Meyerson, M ;

Golub, TR ;

Lee, SJ ;

Gilliland, DG .

CANCER CELL, 2005, 7 (04) :387-397

[10] Allogeneic hematopoietic stern-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia [J].

Rondelli, D ;

Barosi, G ;

Bacigalupo, A ;

Prchal, JT ;

Popat, U ;

Alessandrino, EP ;

Spivak, JL ;

Smith, BD ;

Klingemann, HG ;

Fruchtman, S ;

Hoffman, R .

BLOOD, 2005, 105 (10) :4115-4119

← 1 2 →